Zevra Therapeutics Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Zevra Therapeutics Inc 's ROA in the third quarter of 2026?
Zevra Therapeutics Inc achieved a return on average assets (ROA) of 26.33 % in its third quarter of 2026, this is above ZVRA's average return on assets of -58.9%.
Zevra Therapeutics Inc assets over the 12 months ending in its third quarter of 2026 are valued at $295 million

ROA has improved compared to 20.35% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 35 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 77, from total ROA ranking in the second quarter of 2026 at 137.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	15.32 %	17.89 %	60.88 %	44.59 %	40.55 %
Y / Y Net Income Change	-	-88.77 %	-	-	-
Net Income (TTM) in million	78	58	124	83	35
Return On Assets (TTM)	26.33 %	20.35 %	45.5 %	33.74 %	15.72 %
ZVRA's Total Ranking	# 77	# 137	# 318	# 2037	# 4222
Total Assets (TTM) in million	314	303	279	285	272
Seq. Total Assets Change	3.59 %	8.66 %	-2.16 %	4.72 %	5.89 %
Seq. Net Income Change	128.86 %	-77.85 %	211.47 %	-	-

ZVRA's 5 Years Annual ROA >> Back to ZVRA Management Effectiveness >> Compare ZVRA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 19
Sector	# 36
Overall	# 145

Return On Assets Statistics
High	Average	Low
45.6 %	-58.9 %	-213.39 %
(Mar 31 2026)		(Jun 30 2019)

Financial Statements
Zevra Therapeutics Inc 's Assets	$ 314 million	ZVRA's Balance sheet
Zevra Therapeutics Inc 's Income	$ 19 million	Quarterly ZVRA's Income Statement
ZVRA's Income by Division		See ZVRA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	84.69 %	4.5 %	48.79 %	-12.5 %	1170.15 %
Total Assets in million	333	180	172	116	132
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	83	-106	-46	-42	-9
Annual Return On Assets	25.02 %	-58.59 %	-26.72 %	-35.87 %	-6.46 %

ZVRA's 5 Years Annual ROA >> Back to ZVRA Management Effectiveness >> Compare ZVRA ROA to its Competitors

Comment on ZVRA's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 25.02 % compared to prior year, due to annual net income growth of % to $83.23 million, while value of Zevra Therapeutics Inc 's overall assets grew just by 84.69 % to $332.61 million, compared to $332.61 a year before.

More Return On Assets Ratios
ZVRA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ZVRA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ZVRA's Competitors
Subscribers only: Roa for Zevra Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ZVRA's Customers

You may also want to know
ZVRA's Roi	ZVRA's Inventory Turnover Ratio	ZVRA's Growth Rates	ZVRA's Dividend Comparisons
	ZVRA's Profitability Ratios	ZVRA's Asset Turnover Ratio	ZVRA's Dividend Growth
ZVRA's Roe	ZVRA's Valuation Ratios	ZVRA's Financial Strength Ratios	ZVRA's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Exelixis Inc	63.88 %
Rigel Pharmaceuticals Inc	59.56 %
Lensar Inc	46.55 %
Alnylam Pharmaceuticals Inc	46.08 %
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Protalix Biotherapeutics inc	19.89 %
Electromed Inc	19.73 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %

Date modified: 2026-11-06T12:58:20+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.